This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cempra, Inc. To Present At The Jefferies 2012 Global Healthcare Conference In London

CHAPEL HILL, N.C., Nov. 9, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Jefferies 2012 Global Healthcare Conference in London at 4:20 p.m. GMT, Thursday, Nov. 15, 2012, at the Waldorf Hilton in London. Dr. Fernandes will provide an update of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA™ for the chronic, oral treatment of gram positive pathogens including methicillin-resistant  S. aureus (MRSA) in prosthetic joint infections.

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Investor and Media Contacts: Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 Robert.flamm@russopartnersllc.com

Andreas MarathovouniotisRusso Partners, LLC(212) 845-4235 Andreas.marathis@russopartnersllc.com

 

SOURCE Cempra, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,104.91 -127.11 -0.70%
S&P 500 2,116.91 -9.15 -0.43%
NASDAQ 5,069.0630 -20.2990 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs